Sunshine Biopharma Wins U.S. Patent No. 12,624,066 B2, Stock Drops 5.17% After Reverse Split
SBFM•Sunshine Biopharma received U.S. Patent No. 12,624,066 B2 for PLpro-targeting coronavirus inhibitors and stated compounds are ready for GLP studies. Shares fell 5.17% in after-hours trading after a one-for-ten reverse split effective June 1, capping a 77.99% decline over the past 12 months.
1. Issuance of Coronavirus Treatment Patent
Sunshine Biopharma secured U.S. Patent No. 12,624,066 B2 covering small-molecule inhibitors that target the PLpro enzyme critical to coronavirus replication, granting exclusive rights to its proprietary antiviral compounds.
2. GLP Readiness and Development Plans
The patented compounds are positioned for GLP studies—the mandatory preclinical step before human trials—highlighting the company’s strategy to develop broad-spectrum antivirals resilient to future coronavirus mutations.
3. Reverse Stock Split Triggers 5.17% Drop
On May 29, Sunshine Biopharma announced a one-for-ten reverse stock split effective June 1 to meet Nasdaq bid-price requirements, prompting a 5.17% after-hours share decline as investors weighed impacts on liquidity and compliance.
4. Pipeline and Market Position
Alongside its antiviral program, Sunshine Biopharma markets 60 generic drugs in Canada with 12 additional launches planned in 2026, while advancing an mRNA-LNP liver cancer candidate and the PLpro protease inhibitor through development.
